Clinical trial · Interventional
Hypersight and Ethos In Pediatric Radiotherapy
Hypersight and Ethos In Pediatric Radiotherapy (Peds Ethos)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a single-center, prospective pilot study evaluating the utility of HyperSight CBCT imaging and Ethos adaptive radiation planning in pediatric patients receiving radiation therapy for non-cranial tumors. Twenty patients aged 18 or under will be enrolled. Participants will receive standard-of-care radiation therapy, with the addition of twice-weekly HyperSight CBCT scans. These scans will be used to assess anatomical changes and generate adapted radiation plans using the Ethos platform. Radiation oncologists and radiation therapists will independently evaluate the need for adaptation, and adapted vs. scheduled plans will be compared using dosimetric and anatomical similarity metrics. An optional sub-study will allow anonymized imaging and planning data to be shared with Varian Medical Systems. The study duration will match the patient's treatment course, typically 1-6 weeks, with no additional follow-up beyond standard care.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| HyperSight CBCT scans | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Imaging
- description
- Participants will receive standard-of-care radiation therapy, with the addition of twice-weekly HyperSight CBCT scans.
- interventionNames
- Device: HyperSight CBCT scans
Primary outcomes (3)
- measure
- Dice Similarity Coefficient
- timeFrame
- From baseline (start of radiation treatment) to end of treatment, approximately 6 to 8 weeks.
- description
- Change in Tumor and OAR Anatomy During Pediatric Radiation Therapy Using HyperSight CBCT and Ethos Adaptive Replanning. This outcome measures how tumor and organ-at-risk (OAR) anatomy changes during pediatric radiation therapy using HyperSight CBCT.
- measure
- Hausdorff distance
- timeFrame
- From baseline (start of radiation treatment) to end of treatment, approximately 6 to 8 weeks.
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient (paediatric or adolescent) age 18 or under receiving at least 5 days of radiation therapy * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 3 Exclusion Criteria: \- Patients with primary cranial tumours will be excluded due to the low expected utility of non-contrast CT scans in the delineation of brain edema and brain substructures.
References
Publications (0)
Data not yet available